NEW DELHI: Once relegated to the fringes of lifestyle care, obesity drugs have emerged as one of the world's most powerful growth sectors, ranked by McKinsey alongside AI, EVs and robotics as trillion-dollar opportunities by 2040
5 Figure 3: Pharmacy claims data show that 63% of patients initiating Wegovy or Zepbound in early 2024 remained on therapy at one year, up from 40% in the 2023 cohort
BPC-157 has been investigated for its interactions with angiogenic signaling, nitric oxide pathways, vascular function, and tissue remodeling processes
Supports insulin sensitivity , helping the body use insulin more effectively
So, retatrutide can support both weight loss and better glucose levels
We covered the regulatory landscape in the post on the FDA peptide crackdown